However, clinical studies have found that although the PD‐1/PD‐L1 blocking therapy has achieved an unprecedented sustained response rate in a variety of malignant tumors, most patients have not benefited from the treatment, and some responders have relapsed after a period of response, that is, drug resistance has occurred. The gene discussed is PDCD1; the disease is cancer.